MCRB
Seres Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MCRB fundamentals
Seres Therapeutics (MCRB) released its earnings on Nov 5, 2025: revenue was 351.00K (YoY 0.00%), missed estimates; EPS was 0.94 (YoY +384.85%), missed estimates.
Revenue / YoY
351.00K
0.00%
EPS / YoY
0.94
+384.85%
Report date
Nov 5, 2025
MCRB Earnings Call Summary for Q3,2025
- SER-155 Clinical Momentum: Phase two alloHSCT trial design aligned with FDA, with interim analysis results anticipated within 12 months. Study could validate 77% risk reduction in bacterial BSIs, positioning for potential regulatory approval pathway.
- Expanded Access Potential: CARB-X funding for oral liquid SER-155 formulation targets critically ill patients (e.g., ICU, pediatric) unable to swallow capsules, broadening therapeutic reach and addressing unmet need in antimicrobial resistance.
- Strategic Flexibility: Management pursuing non-dilutive funding and partnerships to advance phase two without equity dilution, maintaining financial discipline amid capital raising efforts.
- Market Expansion: IREC study could unlock $30B+ ICI therapy market, addressing side effects that force treatment interruptions and hospitalizations.
- Financial Resilience: 25% workforce reduction extends cash runway to Q2 2026, supporting dual-track development of SER-155 and pipeline candidates.
EPS
Revenue
Revenue & Expenses
MCRB has released its 2025 Q3 earnings report, with revenue of 351.00K, reflecting a YoY change of NaN%, and net profit of 8.20M, showing a YoY change of -90.76%. The Sankey diagram below clearly presents MCRB's revenue sources and cost distribution.
Key Indicators
Seres Therapeutics (MCRB) key financial stats and ratios, covering profitability, financial health, and leverage.
Seres Therapeutics (MCRB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Seres Therapeutics (MCRB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Seres Therapeutics (MCRB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Seres Therapeutics (MCRB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Seres Therapeutics (MCRB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Seres Therapeutics’s earnings call?What factors drove the changes in Seres Therapeutics's revenue and profit?What guidance did Seres Therapeutics's management provide for the next earnings period?What does Seres Therapeutics do and what are its main business segments?What is the market's earnings forecast for Seres Therapeutics next quarter?What is Seres Therapeutics's gross profit margin?Did Seres Therapeutics beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Seres Therapeutics year over year?
